Sun Pharma Advanced Research Company share price today

Sun Pharma Advanced Research Company Ltd's share price was ₹185.33 at the close on 4 November 2026. It has been rising for 24 weeks. That is 0.2% above its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 16 weeks running.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Sun Pharma Advanced Research Company Ltd is in stage 2. The phase helps read everything below.

In the last 52 weeks it traded between ₹115 and ₹265, and at that close it sat 47% of the way up from that low.

Over the last 11 years the share price moved −35% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 17 July 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

One change stood out: operating margin up 455 points on a year earlier.

1. Operating margin up 455 points on a year earlier

   -85% in the June 2026 quarter, from -540%.

For April to June 2026 (the quarter ended 30 June 2026), Sun Pharma Advanced Research Company reported revenue of ₹40.0 crore, up 300.0% from ₹10.0 crore a year earlier, and a loss of ₹21.0 crore.

Sun Pharma Advanced Research Company results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 8 January 2026, about October to December 2025; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Sun Pharma Advanced Research Company closed at ₹185.33 on 4 November 2026, up 39.0% from ₹133.35 a year earlier (7 November 2025) and down 31.3% over five years. Its highest weekly close since March 2016 was ₹516.05 on 12 January 2018.

Sun Pharma Advanced Research Company share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Sun Pharma Advanced Research Company closed at ₹185.33, up 4.8% on the week and down 4.6% on the month. Results for April to June 2026: Revenue up 300.0% on a year earlier.

Earlier

• 8 Jan 2026: Sun Pharma Advanced Research Company held its results call for October to December 2025.

Sun Pharma Advanced Research Company has paid no dividend on the NSE since 1 April 2021, the start of the period we checked.

No. Sun Pharma Advanced Research Company Ltd paid out 0% of its profit as dividends in each of its last 4 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the NSE corporate-actions record, read 5 November 2026.

On the call for October to December 2025, held on 8 January 2026, Sun Pharma Advanced Research Company's management spoke about the quarter; the main points are below.

“We are entering the new year with significant momentum on the most important parts of this agenda. Even though we have our fair share of challenges, we're genuinely excited about the potential of our clinical and pre-clinical portfolio as we go into the new year”Anil Raghavan, CEO, on the call for October to December 2025

Source: the call transcript.

From the call for October to December 2025, 8 January 2026. The April to June 2026 results are out since, so this part may be out of date until we update it.

Sun Pharma Advanced Research Company is on one of our India lists: Pharma stocks.

Sun Pharma Advanced Research Company Ltd posted a net loss of ₹21.0 Cr in the Jun 2026 quarter. Full-year FY26 profit was ₹1,553 Cr. That loss is 52.5% of the quarter's revenue. The same quarter a year earlier lost ₹52.0 Cr. 11 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Sun Pharma Advanced Research Company Ltd reported ₹40.0 Cr of revenue in the Jun 2026 quarter, +300.0% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 3 years it has grown 98.8% a year on average. The last full year, FY26, came in at ₹1,879 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹1,909 Cr.

FY26 revenue was ₹1,879 Cr, +2,509.7% on the year before.

Recent pace: the last four quarters grew +1,744.5% on average, against 98.8% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +2,836.9%, against +426.0% a year over the last 8 quarters (accelerating).

Sun Pharma Advanced Research Company Ltd's operating margin was −85.0% in the Jun 2026 quarter, 455.0 percentage points higher than the same quarter a year ago. Across 4 years it has been between −532.0% and 85.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +455.1 percentage points on the year while gross margin changed +34.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Sun Pharma Advanced Research Company Ltd's cash-flow history is too short to judge how much of its profit turns into cash. In FY26 its operations used ₹239 Cr of cash, against ₹1,553 Cr of profit. After ₹14.0 Cr of spending on assets, free cash was −₹253 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: the bigger use of cash is spending on new assets, at 1.7× depreciation over three years. The next section checks what that spending is building.

Sun Pharma Advanced Research Company Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 2 days in FY26, down from 50 days in FY23. It spent ₹59.0 Cr on assets over the last 3 years.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹1,879 Cr, each day of that cycle ties up about ₹5.1 Cr, so roughly ₹10.0 Cr is tied up in the business at any time.

Spending on assets: ₹59.0 Cr over the last 3 years, against ₹35.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹72.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Sun Pharma Advanced Research Company Ltd's P/E is 3.8×, with too little history to compare. Its usual P/E (the middle reading) is 4.3×, over 5 months of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple.

Sun Pharma Advanced Research Company Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Sun Pharma Advanced Research Company Ltd earned a ROCE of 164% in FY26. That is up from a low of −279% in FY25. Its return on capital used (ROIC) is 126.2 percentage points above its cost of capital, so growth here adds value, not just size.

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

It comes from a 82.7% net margin and 0.87× asset turnover (sales divided by assets).

Why the return is what it is (FY26): a 82.7% net margin × 0.87× asset turnover × 1.62× leverage (assets divided by equity) ≈ 116.6% on equity. The margin does most of the work; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 138.2% − 12.0% = +126.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.

Sun Pharma Advanced Research Company Ltd has total debt of ₹559 Cr against shareholder equity of ₹1,339 Cr as of Jun 2026, so its debt is 0.42× its equity. Year by year, that ratio went from 2.55 in FY22 to 0.42 in FY26. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Foreign institutions raised their stake in Sun Pharma Advanced Research Company Ltd by 1.5 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 3.7% of the company. Domestic institutions moved −0.5 points over the same period, to 0.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Foreign institutions: +1.5 points over 8 quarters, to 3.7%; Domestic institutions: −0.5 points over 8 quarters, to 0.1%; Promoters: +0.0 points over 8 quarters, to 65.7%.

Why the owners changed: foreign institutions drove it (+1.5 points), with the other side taken by domestic institutions (−0.5 points). They raised their stake step by step.

For Sun Pharma Advanced Research Company Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

61.4 out of 100, rank 4 of 10 in Pharma - Others, with 78% of the evidence available.

Sun Pharma Advanced Research Company Ltd scores 61.4 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 4. Earnings are strong; relative strength in its sector is -17.4% and the one-year return is 30.9%.

The four parts add up to the total exactly: 25.8 + 16.3 + 15 + 4.3 = 61.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Sun Pharma Advanced Research Company ranks 4 of 10 Pharma - Others companies on the 4-Factor Sector Score, with 61.4 out of 100.